메뉴 건너뛰기




Volumn 10, Issue 8, 2014, Pages 1185-1192

Pharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edema

Author keywords

Diabetic macular edema; Expert review; Macugen; Pegaptanib octasodium

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN ANTIBODY; APTAMER; VASCULOTROPIN A;

EID: 84904342296     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.922543     Document Type: Review
Times cited : (11)

References (35)
  • 1
    • 0028275559 scopus 로고
    • Ten-year incidence of visual loss in a diabetic population
    • Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology 1994;101(6):1061-70
    • (1994) Ophthalmology , vol.101 , Issue.6 , pp. 1061-1070
    • Moss, S.E.1    Klein, R.2    Klein, B.E.3
  • 2
    • 63049133469 scopus 로고    scopus 로고
    • Diabetic retinopathy: A growing concern in an aging population
    • Paulus YM, Gariano RF. Diabetic retinopathy: a growing concern in an aging population. Geriatrics 2009;64(2):16-20
    • (2009) Geriatrics , vol.64 , Issue.2 , pp. 16-20
    • Paulus, Y.M.1    Gariano, R.F.2
  • 3
    • 40849137726 scopus 로고    scopus 로고
    • Clinically significant macular edema and survival in type 1 and type 2 diabetes
    • Hirai FE, Knudtson MD, Klein BE, et al. Clinically significant macular edema and survival in type 1 and type 2 diabetes. Am J Ophthalmol 2008;145(4):700-6
    • (2008) Am J Ophthalmol , vol.145 , Issue.4 , pp. 700-706
    • Hirai, F.E.1    Knudtson, M.D.2    Klein, B.E.3
  • 4
    • 79955852527 scopus 로고    scopus 로고
    • Pegaptanib octasodium for the treatment of diabetic macular edema
    • Schartman JP, Coney JM, Hornik JH, et al. Pegaptanib octasodium for the treatment of diabetic macular edema. Expert opin pharmacother 2011;12(8):1317-23
    • (2011) Expert Opin Pharmacother , vol.12 , Issue.8 , pp. 1317-1323
    • Schartman, J.P.1    Coney, J.M.2    Hornik, J.H.3
  • 5
    • 0031793875 scopus 로고    scopus 로고
    • The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII: The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes
    • Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII: the 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105(10):1801-15
    • (1998) Ophthalmology , vol.105 , Issue.10 , pp. 1801-1815
    • Klein, R.1    Klein, B.E.2    Moss, S.E.3    Cruickshanks, K.J.4
  • 6
    • 0028915217 scopus 로고
    • Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial
    • Diabetes Control and Complications Trial Research Group
    • Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995;102:647-61
    • (1995) Ophthalmology , vol.102 , pp. 647-661
  • 8
    • 0022347471 scopus 로고
    • Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1
    • Early Treatment Diabetic Retinopathy Study research group PMID: 2866759
    • Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985;103(12):1796-806. PMID: 2866759
    • (1985) Arch Ophthalmol , vol.103 , Issue.12 , pp. 1796-1806
  • 9
    • 0027370108 scopus 로고
    • The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
    • The Diabetes Control and Complications Trial Research Group PMID: 8366922
    • The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329(14):977-86. PMID: 8366922
    • (1993) N Engl J Med , vol.329 , Issue.14 , pp. 977-986
  • 10
    • 79953299899 scopus 로고    scopus 로고
    • Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema
    • Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118(4):609-14
    • (2011) Ophthalmology , vol.118 , Issue.4 , pp. 609-614
    • Elman, M.J.1    Bressler, N.M.2    Qin, H.3
  • 11
    • 62449171859 scopus 로고    scopus 로고
    • Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema
    • Diabetic Retinopathy Clinical Research Network
    • Diabetic Retinopathy Clinical Research Network. Beck RW, Edwards AR, Aiello LP, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127(3):245-51
    • (2009) Arch Ophthalmol , vol.127 , Issue.3 , pp. 245-251
    • Beck, R.W.1    Edwards, A.R.2    Aiello, L.P.3
  • 12
    • 77952779304 scopus 로고    scopus 로고
    • Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema
    • Diabetic Retinopathy Clinical Research Network
    • Diabetic Retinopathy Clinical Research Network. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117(6):1064-77.e35
    • (2010) Ophthalmology , vol.117 , Issue.6
    • Elman, M.J.1    Aiello, L.P.2    Beck, R.W.3
  • 14
    • 0036959644 scopus 로고    scopus 로고
    • Preclinical and phase 1A clinical evaluation of an anti- VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration
    • Eyetech Study Group
    • Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti- VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;22(2):143-52
    • (2002) Retina , vol.22 , Issue.2 , pp. 143-152
  • 17
    • 84874874434 scopus 로고    scopus 로고
    • Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
    • Thomas M, Mousa SS, Mousa SA. Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration. Clin Ophthalmol 2013;7:495-501
    • (2013) Clin Ophthalmol , vol.7 , pp. 495-501
    • Thomas, M.1    Mousa, S.S.2    Mousa, S.A.3
  • 18
    • 77955657984 scopus 로고    scopus 로고
    • A review of clinical trials of anti-VEGF agents for diabetic retinopathy
    • Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch clin exp ophthalmol 2010;248(7):915-30
    • (2010) Graefes Arch Clin Exp Ophthalmol , vol.248 , Issue.7 , pp. 915-930
    • Nicholson, B.P.1    Schachat, A.P.2
  • 19
    • 84867099927 scopus 로고    scopus 로고
    • Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema
    • FAME Study Group
    • Peter A, Campochiaro PA, Brown DM, et al. FAME Study Group. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Opthalmology 2012;119:2125-32
    • (2012) Opthalmology , vol.119 , pp. 2125-2132
    • Peter, A.1    Campochiaro, P.A.2    Brown, D.M.3
  • 20
    • 77749330682 scopus 로고    scopus 로고
    • Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema
    • Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128(3):289-96
    • (2010) Arch Ophthalmol , vol.128 , Issue.3 , pp. 289-296
    • Haller, J.A.1    Kuppermann, B.D.2    Blumenkranz, M.S.3
  • 21
    • 84857260889 scopus 로고    scopus 로고
    • Ranibizumab: In diabetic macular oedema
    • Frampton JE. Ranibizumab: in diabetic macular oedema. Drugs 2012;72(4):509-23
    • (2012) Drugs , vol.72 , Issue.4 , pp. 509-523
    • Frampton, J.E.1
  • 22
    • 84885022310 scopus 로고    scopus 로고
    • Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: Interim analysis of the RESTORE extension study
    • Lang GE, Berta A, Eldem BM, et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology 2013;120:2004-12
    • (2013) Ophthalmology , vol.120 , pp. 2004-2012
    • Lang, G.E.1    Berta, A.2    Eldem, B.M.3
  • 23
    • 84865593623 scopus 로고    scopus 로고
    • A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: Report 3
    • Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012;130(8):972-9
    • (2012) Arch Ophthalmol , vol.130 , Issue.8 , pp. 972-979
    • Rajendram, R.1    Fraser-Bell, S.2    Kaines, A.3
  • 24
    • 80052512394 scopus 로고    scopus 로고
    • A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections
    • van der Reis MI, La Heij EC, De Jong-Hesse Y, et al. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011;31(8):1449-69
    • (2011) Retina , vol.31 , Issue.8 , pp. 1449-1469
    • Van Der Reis, M.I.1    La Heij, E.C.2    De Jong-Hesse, Y.3
  • 25
    • 84864444516 scopus 로고    scopus 로고
    • One-year outcomes of the da Vinci Study of VEGF. Trap-Eye in eyes with diabetic macular edema
    • Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da Vinci Study of VEGF. Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012;119(8):1658-65
    • (2012) Ophthalmology , vol.119 , Issue.8 , pp. 1658-1665
    • Do, D.V.1    Nguyen, Q.D.2    Boyer, D.3
  • 26
    • 25844513658 scopus 로고    scopus 로고
    • A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema
    • Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112(10):1747-57
    • (2005) Ophthalmology , vol.112 , Issue.10 , pp. 1747-1757
    • Cunningham, Jr.E.T.1    Adamis, A.P.2    Altaweel, M.3
  • 27
    • 22744446011 scopus 로고    scopus 로고
    • Pegaptanib: The first antiangiogenic agent approved for neovascular macular degeneration
    • Doggrell SA. Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration. Expert opin pharmacother 2005;6(8):1421-3
    • (2005) Expert Opin Pharmacother , vol.6 , Issue.8 , pp. 1421-1423
    • Doggrell, S.A.1
  • 28
    • 32844458094 scopus 로고    scopus 로고
    • Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: A review
    • Kourlas H, Schiller DS. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review. Clin ther 2006;28(1):36-44
    • (2006) Clin Ther , vol.28 , Issue.1 , pp. 36-44
    • Kourlas, H.1    Schiller, D.S.2
  • 29
    • 29644444716 scopus 로고    scopus 로고
    • Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals
    • Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113(1):23-8
    • (2006) Ophthalmology , vol.113 , Issue.1 , pp. 23-28
    • Adamis, A.P.1    Altaweel, M.2    Bressler, N.M.3
  • 32
    • 77952506869 scopus 로고    scopus 로고
    • Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: Pan- European experience
    • Sivaprasad S, Hykin P, Saeed A, et al. Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: pan- European experience. Eye(Lond) 2010;24(5):793-8
    • (2010) Eye(Lond) , vol.24 , Issue.5 , pp. 793-798
    • Sivaprasad, S.1    Hykin, P.2    Saeed, A.3
  • 33
    • 84860156429 scopus 로고    scopus 로고
    • Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors
    • Chong V. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. Ophthalmologica 2012;227(Suppl 1):2-10
    • (2012) Ophthalmologica , vol.227 , Issue.SUPPL. 1 , pp. 2-10
    • Chong, V.1
  • 35
    • 84899902749 scopus 로고    scopus 로고
    • Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: The RESTORE Extension Study
    • Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE Extension Study. Ophthalmology 2014;121(5):1045-53
    • (2014) Ophthalmology , vol.121 , Issue.5 , pp. 1045-1053
    • Schmidt-Erfurth, U.1    Lang, G.E.2    Holz, F.G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.